DE60221510D1 - Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung - Google Patents

Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung

Info

Publication number
DE60221510D1
DE60221510D1 DE60221510T DE60221510T DE60221510D1 DE 60221510 D1 DE60221510 D1 DE 60221510D1 DE 60221510 T DE60221510 T DE 60221510T DE 60221510 T DE60221510 T DE 60221510T DE 60221510 D1 DE60221510 D1 DE 60221510D1
Authority
DE
Germany
Prior art keywords
variants
hgf
fragment
factor
hepatocyt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60221510T
Other languages
English (en)
Other versions
DE60221510T2 (de
Inventor
Ermanno Gherardi
Daniel Lietha
Thomas Leon Blundell
Dimitry Yurievich Chirgadze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Cambridge Enterprise Ltd
Original Assignee
Medical Research Council
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Cambridge Enterprise Ltd filed Critical Medical Research Council
Application granted granted Critical
Publication of DE60221510D1 publication Critical patent/DE60221510D1/de
Publication of DE60221510T2 publication Critical patent/DE60221510T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DE60221510T 2001-04-27 2002-04-29 Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung Expired - Lifetime DE60221510T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0110430 2001-04-27
GBGB0110430.6A GB0110430D0 (en) 2001-04-27 2001-04-27 Protein variants and uses thereof
PCT/GB2002/001941 WO2002088354A1 (en) 2001-04-27 2002-04-29 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use

Publications (2)

Publication Number Publication Date
DE60221510D1 true DE60221510D1 (de) 2007-09-13
DE60221510T2 DE60221510T2 (de) 2008-04-17

Family

ID=9913640

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221510T Expired - Lifetime DE60221510T2 (de) 2001-04-27 2002-04-29 Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung

Country Status (11)

Country Link
US (3) US7179786B2 (de)
EP (1) EP1381681B1 (de)
JP (2) JP4637452B2 (de)
AT (1) ATE368741T1 (de)
AU (1) AU2002251337B2 (de)
CA (1) CA2440775C (de)
DE (1) DE60221510T2 (de)
DK (1) DK1381681T3 (de)
ES (1) ES2291460T3 (de)
GB (1) GB0110430D0 (de)
WO (1) WO2002088354A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20050107296A1 (en) * 2001-10-31 2005-05-19 Institut Des Vaisseaux Et Du Sang Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
US7563570B2 (en) 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US20090215686A1 (en) * 2007-03-05 2009-08-27 Huaqiang Eric Xu Nk1-based polypeptides and related methods
CA2743184A1 (en) * 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
WO2011103382A2 (en) * 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
JP6170435B2 (ja) 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
WO2013037521A1 (en) 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2013037520A1 (en) 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
US10435450B2 (en) 2015-01-21 2019-10-08 Centre National De La Recherche Scientifique MET receptor agonist proteins
EP3472178A4 (de) 2016-06-17 2020-02-19 Magenta Therapeutics, Inc. Zusammensetzung und verfahren zur abreicherung von cd117+-zellen
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CN110461876B (zh) 2017-01-20 2024-05-17 海德堡医药研究有限责任公司 用于耗尽cd137+细胞的组合物和方法
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594115A (en) * 1990-04-09 1997-01-14 Pharmacia & Upjohn Company Process of purifying recombinant proteins and compounds useful in such process
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DK0642580T3 (da) 1992-05-18 2002-12-23 Genentech Inc Hepactocytvækstfaktorvarianter
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof

Also Published As

Publication number Publication date
JP2004532032A (ja) 2004-10-21
CA2440775C (en) 2013-02-26
WO2002088354A1 (en) 2002-11-07
DK1381681T3 (da) 2007-10-29
DE60221510T2 (de) 2008-04-17
ATE368741T1 (de) 2007-08-15
CA2440775A1 (en) 2002-11-07
US20080167224A1 (en) 2008-07-10
GB0110430D0 (en) 2001-06-20
US20110021612A1 (en) 2011-01-27
US8232258B2 (en) 2012-07-31
US7795214B2 (en) 2010-09-14
US7179786B2 (en) 2007-02-20
US20040236073A1 (en) 2004-11-25
JP4637452B2 (ja) 2011-02-23
EP1381681A1 (de) 2004-01-21
JP2011045370A (ja) 2011-03-10
EP1381681B1 (de) 2007-08-01
ES2291460T3 (es) 2008-03-01
AU2002251337B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
DE60221510D1 (de) Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
DE69916591T2 (de) Hochzähe, hochfeste amorphe zirkoniumlegierung
EE200300307A (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
DE60039515D1 (de) Zusammensetzung für ersatz für knochentransplantat
BR9916132B1 (pt) composiÇÕes e utilizaÇço das mesmas.
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DE60038922D1 (de) Zusammensetzungen für den wiederaufbau von knochengewebe
GB0222495D0 (en) Compounds
DE69916828D1 (de) Pyrazoline, ihre herstellung und verwendung als medikamente
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
ATA132298A (de) Verschleissmonitor
ATE234812T1 (de) Integrin antagonisten
DE60036959D1 (de) Tensidzusammensetzungen, verbesserungsmittel enthaltend
BR0012327A (pt) Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
SE9904404L (sv) Ny komposition
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
NO20002408D0 (no) 5-HT1F antagonister
BR9811694A (pt) Forno de cúpula.
DE50010676D1 (de) Sequenzvarianten des menschlichen beta-1-adrenozeptorgens und ihre verwendung
ITMI20020624A0 (it) Composizioni ad attivita' biostimolante

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: GHERARDI, ERMANNO, CAMBRIDGE CAMBRIDGESHIRE CB, GB

Inventor name: LIETHA, DANIEL, CAMBRIDGE, CAMBRIDGESHIRE CB2 , GB

Inventor name: BLUNDELL, THOMAS LEON, CAMBRIDGE, CAMBRIDGESHI, GB

Inventor name: CHIRGADZE, DIMITRY YURIEVICH, CAMBRIDGE, CAMBR, GB

8364 No opposition during term of opposition